CONSOLIDATED STATEMENTS OF EQUITY - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Treasury	Additional Paid-In Capital	Additional Paid-In Capital Cumulative Effect, Period of Adoption, Adjustment	AOCI Attributable to Parent [Member]	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment
Beginning balance, shares (in shares) at Dec. 31, 2021			690,082,283
Beginning balance, shares (in shares) at Dec. 31, 2021				(8,655,082)
Beginning balance at Dec. 31, 2021	$ 1,685,126	$ (21,642)	$ 6,901	$ (1,791)	$ 3,222,487	$ (39,100)	$ (30,495)	$ (1,511,976)	$ 17,458
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity-based compensation expense	7,617				7,617
Exercise of common stock options and warrants (in shares)			55,750
Exercise of common stock options and warrants	136		$ 1		135
Net loss	(55,433)							(55,433)
Other comprehensive income (loss)	(920)						(920)
Ending balance, shares (in shares) at Mar. 31, 2022			690,138,033
Ending balance, shares (in shares) at Mar. 31, 2022				(8,655,082)
Ending balance at Mar. 31, 2022	$ 1,614,884		$ 6,902	$ (1,791)	3,191,139		(31,415)	(1,549,951)
Beginning balance, shares (in shares) at Dec. 31, 2022			781,306,164
Beginning balance, shares (in shares) at Dec. 31, 2022	(8,655,082)			(8,655,082)
Beginning balance at Dec. 31, 2022	$ 1,561,648		$ 7,813	$ (1,791)	3,421,872		(43,323)	(1,822,923)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Equity-based compensation expense	2,717				2,717
Net loss	(18,267)							(18,267)
Other comprehensive income (loss)	$ 5,712						5,712
Ending balance, shares (in shares) at Mar. 31, 2023			781,306,164
Ending balance, shares (in shares) at Mar. 31, 2023	(8,655,082)			(8,655,082)
Ending balance at Mar. 31, 2023	$ 1,551,810		$ 7,813	$ (1,791)	$ 3,424,589		$ (37,611)	$ (1,841,190)